Dr. Anna Broder’s research focuses on improving outcomes in systemic lupus erythematosus and inflammatory arthropathies. She also studies how cardiovascular disease, kidney disease, and the presence of antiphospholipid antibodies affect outcomes in autoimmune diseases. She has experience working with large cohorts and databases, as well as with recruiting lupus and rheumatoid arthritis patients for ongoing clinical trials.
Dr. Broder is the Primary Investigator for the Einstein Rheumatic Diseases registry that includes clinical data and samples for over 1000 patients with rheumatologic diseases. The primary focus of her research is lupus-related kidney disease. She is studying lupus activity and medications in patients with lupus-related end stage kidney disease. Dr. Broder is investigating the biomarkers of tubulointerstitial damage in early lupus nephritis in the hopes to prevent progression to end stage kidney disease. Her work is supported by funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Dr. Broder earned her undergraduate degree with Honors in Mathematics and General Scholarship from Trinity College in Hartford, CT. She subsequently worked as a database administrator and a statistician before entering medical school. Dr. Broder received her medical degree from the University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School in 2004. Dr. Broder completed her Internal Medicine Residency in 2007, and her Rheumatology Fellowship in 2009, both at Montefiore. She has also received a Master’s Degree in Clinical Research Methods (with Honors) from the Einstein Clinical Research Training Program in 2010. Dr. Broder joined the Division of Rheumatology in 2009.
Special interest: Lupus; pregnancy and lupus; lupus-related kidney disease; hematologic manifestations of systemic lupus.
Other rheumatologic conditions: Systemic sclerosis; vasculitis; inflammatory myopathies